Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
L

Not yet reviewed: this article is pending editorial review by Lyrea.

3-MeO-PCPr

3-MeO-PCPr molecule structure3-MeO-PCPr molecule structure
3-Methoxy-N-propylphencyclidamine
3-Methoxyphencyclidine propylamino
Chemical Class
Arylcyclohexylamine

3-MeO-PCPr is a dissociative research chemical of the arylcyclohexylamine class.citation needed It is the N-propyl homologue of 3-MeO-PCE and is reported to be slightly less potent than PCP while producing a somewhat less manic experience by comparison. As a relatively obscure research chemical, very limited data exists regarding its safety profile, pharmacology, and long-term effects. Like other arylcyclohexylamines, it may carry a risk of habit formation.1

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~1 mg
Light1-3 mg
Moderate3-8 mg
Strong8-15 mg
Heavy15+ mg

Duration

Onset5-10 minutes
Total1-3 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Available documentation of 3-MeO-PCPr is minimal and consists mainly of comparative characterization rather than detailed accounts of the experience. It is described as somewhat less potent than PCP, and as producing a less manic quality than related compounds.

See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives

Pharmacology

Pharmacodynamics

Published literature places 3-MeO-PCPr among arylcyclohexylamines perceived as ketamine-like dissociatives and believed to act predominantly through NMDA-receptor antagonism. The compound-specific study was analytical, not a clinical pharmacology study, so this is not a complete receptor profile or evidence of human efficacy. [S1][S2]2

Pharmacokinetics

The inspected analytical paper and PCP-NPS review reported no compound-specific absorption, bioavailability, distribution, metabolism, elimination, or half-life values for 3-MeO-PCPr; numerical pharmacokinetic fields should remain empty. [S1][S2]citation needed

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Cross Tolerance

Dissociatives (NMDA receptor antagonists)

Harm Potential

Addiction & Dependence

Psychological

Moderate

Classified as habit-forming, though specific addiction potential has not been formally characterized.

History & Culture

Online documentation

A surviving Bluelight thread dated 2 October 2011 contains a self-report and discussion of 3-MeO-PCPr. This establishes online discussion by that date, not first synthesis or first use.3

Legality

International

As of 23 August 2026, 3-MeO-PCPr (N-propyl-1-(3-methoxyphenyl)cyclohexan-1-amine) is not named or chemically designated in the current complete INCB Yellow, Green or Red Lists. The Green List instead places PCE (N-ethyl-1-phenylcyclohexylamine) and PHP/PCPy (1-(1-phenylcyclohexyl)pyrrolidine) in Schedule I and separately places 3-methoxyphencyclidine (1-(1-(3-methoxyphenyl)cyclohexyl)piperidine) in Schedule II. Those exact designations do not cover the target, which the analytical literature identifies as the 3-methoxyphenyl N-propyl compound rather than the N-ethyl, pyrrolidine or piperidine compounds. The Green List extends control to salts and applicable stereoisomers of listed substances, not to otherwise distinct N-alkyl analogues. INCB's March 2026 notice adds only MDMB-FUBINACA to Schedule II, with effect from 25 November 2026, and does not name 3-MeO-PCPr. The current INCB materials therefore establish no scheduling of 3-MeO-PCPr under the 1961, 1971 or 1988 Conventions.

By Country

Illegal14
Argentina flagArgentinaIllegal (analog/blanket ban)
Australia flagAustraliaIllegal (analog/blanket ban)
Austria flagAustriaIllegal (analog/blanket ban)
Canada flagCanadaIllegal (analog/blanket ban)
Germany flagGermanyIllegal (analog/blanket ban)
Ireland flagIrelandIllegal (analog/blanket ban)
New Zealand flagNew ZealandIllegal (analog/blanket ban)
Poland flagPolandIllegal (analog/blanket ban)
Russia flagRussiaIllegal (analog/blanket ban)
Singapore flagSingaporeIllegal (analog/blanket ban)
South Africa flagSouth AfricaIllegal (analog/blanket ban)
South Korea flagSouth KoreaIllegal (analog/blanket ban)
Switzerland flagSwitzerlandIllegal (analog/blanket ban)
United Kingdom flagUnited KingdomIllegal (analog/blanket ban)

References

Source Pages

  1. IsomerDesign: PIHKAL Entry for 3-MeO-PCPr
  2. TripSit Factsheet: 3-MeO-PCPr

Citations

  1. Ryu IS, Kim OH, Lee YE, Kim JS, Li ZH, Kim TW, Lim RN, Lee YJ, Cheong JH, Kim HJ, Lee YS, Steffensen SC, Lee BH, Seo JW, & Jang EY. (2020). The Abuse Potential of Novel Synthetic Phencyclidine Derivative 1-(1-(4-Fluorophenyl)Cyclohexyl)Piperidine (4′-F-PCP) in Rodents. 21(13). https://doi.org/10.3390/ijms211344801
  2. Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, Dempster NM, & Brandt SD. (2016). Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. pubmed.ncbi.nlm.nih.gov, 8(8), 801-815. https://doi.org/10.1002/dta.1861123
  3. Bluelight community thread, posted 2 October 2011. bluelight.org (n.d.). https://www.bluelight.org/community/threads/3-meo-pcpr.592033/1
  4. Controlled Drugs and Substances Act, Schedule I, item 14. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
  5. Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r., załącznik nr 3 część 8. eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
  6. Government Decree No. 681 of 30 June 1998, List I and note 6. eec.eaeunion.org (n.d.). https://eec.eaeunion.org/upload/medialibrary/ce5/jxs8zar8pwnvwhjinle1v2k0o4u2i77h/Drugs_RU_2025.pdf1
  7. Neue-Psychoaktive-Substanzen-Verordnung, Anlage II group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
  8. Neue-Psychoaktive-Substanzen-Verordnung, Anlage II group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/i/2011/146/P4/NOR401344471
  9. Neue-psychoaktive-Stoffe-Gesetz, Anlage 1 no. 6. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
  10. Criminal Justice (Psychoactive Substances) Act 2010, sections 1 and 3. irishstatutebook.ie (n.d.). https://www.irishstatutebook.ie/eli/2010/act/22/section/1/enacted/en/html1

Further Reading

  1. Substance Search: 3-MeO-PCPr
  2. Tripsitter: Arylcyclohexylamines

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 3-MeO-PCPr article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.